TAK - Takeda Pharmaceutical Co Ltd ADR - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

with an average price target of $17.36. This is a potential upside of $2.29 (15.2%) from yesterday's end of day stock price of $15.07.

Takeda Pharmaceutical Co Ltd ADR's activity chart (see below) currently has 9 price targets and 5 ratings on display.

Stock Analyst Price Targets - Review

Most recent stock forecast was given by KEN CACCIATORE from TD COWEN on 16-May-2023.

Best performing analysts who are covering TAK - Takeda Pharmaceutical Co Ltd ADR:

Ken Cacciatore Stephen Barker

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Ken Cacciatore (TD COWEN)

Buy

$20

$4.8 (31.58%)

$30

2 years 1 months ago
(16-May-2023)

0/5 (0%)

$4.58 (29.70%)

Please subscribe to see the analyst performance score

Stephen Barker (JEFFERIES)

Please subscribe to see the analyst performance score

Show more analysts

Load Price Targets and Ratings Chart

To gain access for the analyst/ stock price target chart please use a computer

What is TAK (Takeda Pharmaceutical Co Ltd ADR) average time for price targets to be met?

On average it took 0 days on average for the stock forecasts to be realized with a an average price target met ratio 0

Which analyst has the current highest performing score on TAK (Takeda Pharmaceutical Co Ltd ADR) with a proven track record?

KEN CACCIATORE

Which analyst has the current lower performing score on TAK (Takeda Pharmaceutical Co Ltd ADR) with a proven track record?

STEPHEN BARKER

Which analyst has the most public recommendations on TAK (Takeda Pharmaceutical Co Ltd ADR)?

Ken Cacciatore has 15 price targets and 11 ratings on TAK

Which analyst is the currently most bullish on TAK (Takeda Pharmaceutical Co Ltd ADR)?

Ken Cacciatore with highest potential upside - $4.8

Which analyst is the currently most reserved on TAK (Takeda Pharmaceutical Co Ltd ADR)?

Stephen Barker with lowest potential downside - -$0

Takeda Pharmaceutical Co Ltd ADR in the News

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024 Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings Up to Six New Molecular Entities in Phase 3 Development in FY2025 with Three Phase 3 Data Readouts Recently Completed or Anticipated...

TAK or DSNKY: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical – Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. – Sponsored ADR (DSNKY). But which of these two stocks is more attractive to value investors? We’ll need to take a closer look to find out. There are plenty of strategies...